Skip to content

Effectiveness and Safety of Implantable Neurostimulation Systems for Chronic Pain: A Spanish Multicenter Study (STIM-RENASED)

Effectiveness and Safety of Implantable Neurostimulation Systems for the Treatment of Chronic Refractory Pain in Spain: Prospective Multicenter Study From the Spanish Pain Society Registry (STIM-RENASED)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05770700
Acronym
STIM-RENASED
Enrollment
504
Registered
2023-03-15
Start date
2023-04-01
Completion date
2025-04-01
Last updated
2024-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain

Keywords

Spinal cord stimulation, Dorsal root ganglion stimulation, Peripheral nerve stimulation

Brief summary

Chronic pain is a prevalent condition that negatively affects patients' quality of life. Implantable neurostimulation therapies have been proposed as a treatment option for chronic pain. However, real-world data on the effectiveness and safety of these therapies in Spain are scarce. This study aims to obtain real-world data on the effectiveness and safety of implantable stimulation systems for chronic pain treatment in Spain.

Detailed description

All Spanish hospitals that implant neurostimulation systems for pain treatment will be invited to participate in the study. Patients will be recruited before the procedure, and before providing data to the registry, the study will be explained to them, and they will sign an informed consent form. Demographic data related to the pathology and procedure will be collected. Follow-up will be conducted at six and twelve months after the procedure.

Interventions

None listed

Sponsors

Sociedad Espanola del Dolor
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Chronic refractory pain patients candidates for treatment with an implantable neurostimulation system. * Accept to participate in the study and sign informed consent.

Exclusion criteria

* Patients in whom it would be difficult to complete follow-up. * Insufficient understanding of the Spanish language. * Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Percentage of patients with at least 50 % pain relief in the area of their predominant pain at one year.Twelve monthsPercentage of patients who experience a reduction of at least 50% in the intensity of their predominant pain compared to the initial value, assessed twelve months after the implantation of the neurostimulation system. Pain intensity will be measured using an 11-point Numeric Pain Rating Scale (NPRS), with a range from 0 (no pain) to 10 (maximum pain possible)

Secondary

MeasureTime frameDescription
Percentage of patients with at least 50 % pain relief in the area of their non-predominant pain at one year.Six and twelve monthsPercentage of patients who experience a reduction of at least 50% in the intensity of their non-predominant pain compared to the initial value, assessed six and twelve months after the implantation of the neurostimulation system. Pain intensity will be measured using an 11-point Numeric Pain Rating Scale (NPRS), with a range from 0 (no pain) to 10 (maximum pain possible)
Compared change from baseline on health-related quality of life scores (EQ Index)Six and twelve monthsThe impact of the treatment on the patient's health-related quality of life will be evaluated using the EQ-5D-5L questionnaire at six and twelve months after implantation. The EQ-5D-5L assesses quality of life across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain is scored on a scale of 1 (no problems) to 5 (extreme problems), generating a 5-digit code that corresponds to the patient's health status.
Percentage of patients with at least 50 % pain relief in the area of their predominant pain at six months.Six monthsPercentage of patients who experience a reduction of at least 50% in the intensity of their predominant pain compared to the initial value, assessed six months after the implantation of the neurostimulation system. Pain intensity will be measured using an 11-point Numeric Pain Rating Scale (NPRS), with a range from 0 (no pain) to 10 (maximum pain possible)
Patient SatisfactionSix and twelve monthsPercentage of implanted subjects satisfied with the treatment at six and twelve months after the implantation of the neurostimulation system. defined as indicating: since the start of the therapy has the pain improved? yes/no, Are you satisfied with the treatment? yes/no or would you agree to the treatment again? yes/no
Number of Adverse Events as a Measure of SafetySix and twelve monthsNumber and percentage of patients with adverse effects related to therapy at six and twelve months after implantation of the neurostimulation system.
Patient Global Impression of ImprovementSix and twelve monthsAssessment of clinical global impression of improvement using the PGI-I scale at six and twelve months after implantation of the neurostimulation system. The PGI-I score ranges from 1 (Very much better) through to 7 (Very much worse). The lower the score, the better the improvement.

Countries

Spain

Contacts

Primary ContactAntonio Ojeda, MD
renased@sedolor.es0034911729144

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026